Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/SCN2A Encephalopathy

Neurological & Neuromuscular

SCN2A Encephalopathy Clinical Trials and Treatments

Also called SCN2A-DEE, SCN2A-Related Disorders, SCN2A Developmental and Epileptic Encephalopathy, SCN2A Epilepsy, SCN2A-Related Epilepsy, Nav1.2 Channelopathy, SCN2A Autism

Nerve cells talk to each other with electrical pulses, and those pulses depend on tiny doors in the cell membrane that let sodium in. SCN2A carries the instructions for one of those doors, a channel called Nav1.

In plain words, SCN2A encephalopathy is a rare genetic condition caused by a change in a gene that brain cells need to send signals. Some children have seizures from the first days of life, while others mainly have autism and slower development.

Get an email when new SCN2A Encephalopathy trials open or the FDA decides. Get alerts

SCN2A Encephalopathy

Where treatments stand, from ClinicalTrials.gov and FDA labels

Also 1 study with no phase, like observational studies.

FDA review1

Relutrigine, Dec 27, 2026

FDA-approved medicines0

No medicine's current FDA label names SCN2A Encephalopathy yet.

SCN2A Encephalopathy has no FDA-approved medicines, 2 open or active clinical trials (2 recruiting), and a pending FDA decision on Relutrigine, due Dec 27, 2026.

Labels checked October 21, 2026.Download the data

More about SCN2A Encephalopathy

2. A change in the gene can jam the door open, so the cell fires too easily, or stick it shut, so the cell cannot fire well enough. Those 2 faults produce 2 different conditions from the same gene.

Keep reading about SCN2A Encephalopathy

Gain-of-function changes cause early seizures and the brain injury that repeated seizures bring, which is what doctors mean by developmental and epileptic encephalopathy. Loss-of-function changes more often cause autism, intellectual disability and movement problems, with seizures arriving later if at all.

That split matters for treatment, and it is not something a genetic test report states on its own. Anti-seizure medicines that block sodium channels, such as phenytoin, carbamazepine, oxcarbazepine and lamotrigine, are considered contraindicated when the channel is underactive, so the functional effect of the variant shapes which medicines are safe to try. Families often need a neurologist or geneticist familiar with the specific variant to work out which side of the line their child falls on.

Many children with SCN2A encephalopathy need several seizure medicines at once. Feeding tubes, physical, occupational and speech therapy, and careful seizure monitoring are part of daily life for many families, and the risk of sudden unexpected death in epilepsy (SUDEP) is a conversation every care team should have.

What are the symptoms of SCN2A Encephalopathy?

These are common symptoms of SCN2A Encephalopathy, and how strong they are varies from person to person.

  • Seizures beginning in the first days or months of life, often of several types and often hard to control
  • Developmental delay, or loss of skills a child had already gained
  • Autism or autism-like behavior, with or without seizures
  • Low muscle tone, feeding difficulty and trouble with balance or coordination
  • Abnormal movements such as stiffening, jerking or writhing
  • Intellectual disability, from mild to severe

Who gets SCN2A Encephalopathy?

SCN2A changes almost always arise new in the child (de novo) rather than being inherited, so there is usually no family history. The timing of the first seizure is a clue to the type: seizures before 3 months of age usually mean the channel is overactive (gain of function), while seizures after 3 months, or autism without seizures, more often mean it is underactive (loss of function) or has mixed effects.

A milder form, self-limited infantile epilepsy, often runs in families and causes seizures between 3 and 20 months that stop within about a year with normal development. The FamilieSCN2A Foundation estimates that about 75% of cases are still undiagnosed because genetic testing for autism is not routine.

Next steps: find trials you might fitsee what is being testedget help payingget alerts

Which new SCN2A Encephalopathy medicines are in trials?

Investigational medicines Trial Friend tracks for SCN2A Encephalopathy, with trial results, safety findings and where each one stands.

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

Genetic testing for SCN2A Encephalopathy

Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.

Finding labs...

Trusted SCN2A Encephalopathy resources

Reputable organizations and medical references for learning more about SCN2A Encephalopathy, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for SCN2A Encephalopathy

Use this SCN2A Encephalopathy clinical trial finder to see the 2 studies recruiting patients in the United States and worldwide, with eligibility criteria in plain English. Of these, 1 tests a treatment and 1 is an observational study or registry; each card says which. Every trial comes from ClinicalTrials.gov.

FDA decision ahead: Relutrigine, due December 27, 2026. All upcoming decisions

Jump to the trial list, the site map or the pipeline timeline.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

2 active trials worldwide
Filter:
Sort:
RecruitingTreatment trialPhase 3Updated a few months agoNCT07019922

A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety

Intervention: 1mg elsunersen, 0.5mg elsunersen

Sponsor: Praxis Precision Medicines

A Multi-Center, Single-Arm Clinical Trial to Investigate the Efficacy and Safety of Elsunersen in Pediatric Participants with Early Onset SCN2A Developmental and Epileptic Encephalopathy

Ages 1 Day to 18 Years
Started Aug 2025Updated 3 months agoEst. Dec 2026 (~1 month)
RecruitingPatient registry covering many conditionsUpdated a few months agoNCT01238250

Online Study of People Who Have Genetic Changes and Features of Autism: Simons Searchlight

Sponsor: Simons Searchlight

Simons Searchlight is an observational, online, international research program for families with rare genetic variants that cause neurodevelopmental disorders and may be associated with autism. Simons Searchlight collects medical, behavioral, learning, and developmental informati...

Ages not specified2 locations
Started Oct 2010Updated 4 months agoEst. Oct 2050 (~23y 11m)
Find SCN2A Encephalopathy trials near you, ranked by distance →
Active trial locations8 cities in the US
A study site. Select it to see its trials and get directions. Several sites close together. Select the number to zoom in.

Trial Pipeline

Jan 2021 to Nov 2031
2021
2023
2025
2027
2029
2031
now
Phase 3
Observational
RecruitingNot yet recruitingDelayed startTodayHover a bar for trial details

Read more about SCN2A Encephalopathy trials

Need help understanding these trials?
Answers with sources, in plain English
Start withor ask
Run a SCN2A Encephalopathy foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

SCN2A Encephalopathy patient communities

Facebook groups, Reddit communities and YouTube channels where SCN2A Encephalopathy patients, caregivers and advocacy groups talk.

Companies developing SCN2A Encephalopathy treatments

Drugmakers that list SCN2A Encephalopathy in their rare disease portfolio, 1 in all.

Questions people ask about SCN2A Encephalopathy